Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jun 23;18(6):326.
doi: 10.3390/md18060326.

In Vitro and In Vivo Assessment of the Efficacy of Bromoageliferin, an Alkaloid Isolated from the Sponge Agelas dilatata, against Pseudomonas aeruginosa

Affiliations

In Vitro and In Vivo Assessment of the Efficacy of Bromoageliferin, an Alkaloid Isolated from the Sponge Agelas dilatata, against Pseudomonas aeruginosa

Dawrin Pech-Puch et al. Mar Drugs. .

Abstract

The pyrrole-imidazoles, a group of alkaloids commonly found in marine sponges belonging to the genus Agelas, display a wide range of biological activities. Herein, we report the first chemical study of the secondary metabolites of the sponge A. dilatata from the coastal area of the Yucatan Peninsula (Mexico). In this study, we isolated eight known alkaloids from an organic extract of the sponge. We used NMR and MS analysis and comparison with existing databases to characterize the alkaloids: ageliferin (1), bromoageliferin (2), dibromoageliferin (3), sceptrin (4), nakamuric acid (5), 4-bromo-1H-pyrrole-2-carboxylic acid (6), 4,5-dibromopyrrole-2-carboxylic acid (7) and 3,7-dimethylisoguanine (8). We also evaluated, for the first time, the activity of these alkaloids against the most problematic multidrug-resistant (MDR) pathogens, i.e., the Gram-negative bacteria Pseudomonas aeruginosa, Klebsiella pneumoniae and Acinetobacter baumannii. Bromoageliferin (2) displayed significant activity against P. aeruginosa. Comparison of the antibacterial activity of ageliferins 1-3 (of similar structure) against P. aeruginosa revealed some relationship between structure and activity. Furthermore, in in vitro assays, 2 inhibited growth and biofilm production in clinical strains of P. aeruginosa. Moreover, 2 increased the survival time in an in vivo Galleria mellonella model of infection. The findings confirm bromoageliferin (2) as a potential lead for designing new antibacterial drugs.

Keywords: Agelas dilatata; Galleria mellonella; Pseudomonas aeruginosa; Yucatan Peninsula; antibacterial; biofilm inhibition; pyrrole-imidazole alkaloids; structure-activity relationships.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Stuctures of alkaloids 18, isolated from the sponge A. dilatata, and of TAGE.
Figure 2
Figure 2
Influence of the presence of bromine atoms in A and B pyrrol rings in the antibacterial activity of compounds 13 against P. aeruginosa ATCC 27853 strain.
Figure 3
Figure 3
Quantification of biofilm formation after 24 h by P. aeruginosa strains PAO1 and ATCC 27853 in the presence of different concentrations of bromoageliferin (2).
Figure 4
Figure 4
Survival of G. mellonella larvae (n = 15 per group) following infection with P. aeruginosa strain ATCC 27853 untreated (PBS) and treated with bromoageliferin (2) (2 mg/kg).

Similar articles

Cited by

References

    1. Dolgin E. Sequencing of superbugs seen as key to combating their spread. Nat. Med. 2010;16:1054. doi: 10.1038/nm1010-1054a. - DOI - PubMed
    1. Dadgostar P. Antimicrobial resistance: Implications and costs. Infect. Drug Resist. 2019;12:3903–3910. doi: 10.2147/IDR.S234610. - DOI - PMC - PubMed
    1. World Health Organization (WHO) Antimicrobial Resistance-Global Report on Surveillance. [(accessed on 23 May 2014)];2014 Available online: http://apps.who.int/iris/bitstream/10665/112642/1/9789241564748_eng.pdf.
    1. Donlan R.M., Costerton J.W. Biofilms: Survival mechanisms of clinically relevant microorganisms. Clin. Microbiol. Rev. 2002;15:167–193. doi: 10.1128/CMR.15.2.167-193.2002. - DOI - PMC - PubMed
    1. Newman D.J., Cragg G.M. Natural Products as Sources of New Drugs from 1981 to 2014. J. Nat. Prod. 2016;79:629–661. doi: 10.1021/acs.jnatprod.5b01055. - DOI - PubMed

MeSH terms

LinkOut - more resources